ERElena S. Romanova

Elena S. Romanova

*This is an algorithmically generated author record based on publicly available information.

Elena S. Romanova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and laboratory characteristics of patients with severe COVID-19 undergoing gene engineering therapy

    by Aleksandra V. Rogozhkina, Margarita N. Pogromskaya, Elena S. Romanova, Galina Yu. Startseva, Olga M. Filipovich, Margarita V. Klur, Vsevolod M. Antonov

    Background: One of the primary factors contributing to an increased risk of fatal outcomes in severe COVID-19 cases is the development of a cytokine storm, a hyperimmune response characterized by excessive cytokine release. Despite using biologic therapies, mortality rates in severe COVID-19 cases remain significantly high. Aim: To analyze and evaluate the clinical and laboratory parameters of patients with severe COVID-19 who received biologic therapy. Materials and methods: A cluster sampling method was employed, with clusters selected based on the severity of the primary disease and biologic therapy. The study included 65 patients, divided into two groups based on disease outcomes: Group 1 comprised 34 patients with favorable outcomes, while Group 2 included 31 patients with fatal outcomes. Results: Significant differences were observed between the groups in terms of age (p = 0.01). Patients in Group 2 (with fatal outcomes) had a higher burden of co-morbidities, as measured by the Charlson Comorbidity Index (p = 0.00009) and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G; p = 0.000003). Additionally, the groups differed significantly in the number of days from disease onset to the initiation of biologic therapy (p = 0.02). In Group 2, delayed initiation of biologic therapy was associated with persistently high concentrations of acute-phase proteins. Conclusions: Key factors influencing the efficacy of biologic therapy for severe COVID-19 with cytokine storm include patient age, the presence and severity of co-morbidities, and the timing of hospitalization and initiation of biologic therapy.

  • Open Access

    Acute iucterine hepatitis as a manifestation of severe autoimmune hepatitis

    by Nikolai I. Kuznetsov, Valery V. Vasiliev, Elena S. Romanova, Galina Yu. Startseva, Ivan P. Fedunyak, Vladimir B. Musatov, Alexander М. Alekseev, Васильев Валерий Викторович

    In the article, on the example of a clinical case, a variant of the course of severe acute autoimmune hepatitis type II in a 20-year-old woman is analyzed. The prevalence of this disease are presented. Possible types of autoimmune hepatitis course are discussed. The main diagnostic criteria that indicate the likelihood of autoimmune hepatitis and the tactics of managing these patients are described. This clinical case demonstrates that in the absence of epidemiological, anamnestic data indicating a possible viral or toxic liver damage, it is necessary to think and exclude autoimmune liver damage. It is believed that the level of gamma globulin exceeding more than 1.5 times the upper limit of normal and the absence of viral hepatitis are independent predictors of the presence of autoimmune hepatitis, and the earlier immunosuppressive therapy is started, the more favorable the prognosis of the disease.

  • Open Access

    The problem of toxoplasmosis in outpatient practice. Part I. Toxoplasmosis in immunocompromised patients

    by Valerii V. Vasiliev, Elena S. Romanova, Васильев Валерий Викторович

    Toxoplasmosis remains one of the most common opportunistic infections in immunocompromised patients, primarily in people living with HIV. An increase in the number of requests for medical care by patients with HIV infection as the disease progresses determines the need for knowledge of outpatient therapists and general practitioners of decision-making algorithms for suspected toxoplasmosis in such patients. The main clinical manifestations of toxoplasmosis in patients with immunodeficiency states, the formulation of a preliminary diagnosis, and the routing algorithm are given.


  • Open Access

    Outpatient treatment of patients with COVID-19: Normative documents and/or clinical thinking

    by Valery V. Vasiliev, Elena S. Romanova, Galina Yu. Startseva, Nikolay I. Kuznetsov

    The legal framework for the provision of medical care, its evaluation and control of quality in Russia requires the attending physician to strictly comply with the provisions of regulatory documents. At the same time, clinical practice shows that the recommended algorithms for the provision of care do not allow in all situations to provide medical care of adequate quality. Analysis of the clinical example shows that in the era of the COVID-19 pandemic, in addition to compliance with the established rules, a thorough assessment of a specific clinical situation in the dynamics of development is necessary and timely correction of treatment and diagnostic measures, including those in excess of the established requirements, are required. The methods of remote monitoring of the patients condition need to be improved, since in their current form they do not provide an objective assessment of the patients condition. Face-to-face examinations of patients with COVID-19 receiving medical care at home should be carried out at least every 72 hours, regardless of the result of the remote assessment. The absence of the effect of therapy within three days may be an indication for transferring the patient to a higher level of medical care.

  • Open Access

    Ante- and postnatal diagnostics and complex treatment of congenital cytomegalovirus infection

    by N. V. Rogozina, В. В. Васильев, A. A. Grineva, A. V. Mikhailov, T. A. Kashtanova, A. N. Romanovskiy, R. A. Ivanova, E. S. Romanova, G. M. Ushakova

    Timely diagnostics and treatment of cytomegalovirus infection in pregnant women and newborns allow to avoid serious consequences, preserving the life and health of the child. The article provides an example of antenatal diagnosis of congenital cytomegalovirus infection in the fetus (positive result of polymerase chain reaction in umbilical cord blood), treatment with umbilical transfusion of donor red blood cells, postnatal therapy with antiviral drugs, including ganciclovir and specific immunoglobulin. The issues of assessing the risk of congenital cytomegalovirus infection, approaches to its prevention and treatment during pregnancy are discussed.


  • COMPARATIVE ANALYSIS OF DOMESTIC AND FOREIGN CLINICAL GUIDELINES FOR CURRENT CONGENITAL INFECTIOUS DISEASES

    by V.V. Vasilev, N.V. Rogozina, R.A. Ivanova, G.M. Ushakova, A.A. Grineva, N.V. Skripchenko, E.S. Romanova

    Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.